Blueprint Medicines showcases Ayvakit® data highlighting survival benefits and disease-modifying potential in systemic mastocytosis at ASH 2024
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the… read more.
